Hot Stocks in the News - June 18, 2025

2025-06-18 10:24:44 ET

DENVER, Colo., Jun 18, 2025 ( 247marketnews.com )- Venu (NYSE:VENU) is making waves after announcing the groundbreaking of a $350 million amphitheater in McKinney, Texas—touted as the largest fully seated, multi-seasonal amphitheater ever constructed. In an interview on the Schwab Network, Founder and CEO J.W. Roth shared that Venu is currently developing $1.2 billion worth of entertainment venues, with a $3 billion buildout pipeline targeted over the next 3–4 years. The company leverages an effective financing model combining public-private partnerships (PPP), fractional ownership, and sale-leasebacks. Roth highlighted Venu’s financing model: “35 to 45% of our financing comes from municipality partnerships… another 35–45% from fractional ownership… the rest usually in the form of a sale leaseback.”

Please click here to view the interview.

Venu also filed an 8-K confirming the close of a $10.25 million equity investment with an institutional investor at a premium , with convertible preferred shares priced effectively at $15 per share .

KWESST (NASDAQ:KWE) received a prototype order for its next-gen Battlefield Laser Detection System (BLDS) for a major North American armored vehicle program. The BLDS tech, which detects laser-guided threats like LTDs and LRFs, is designed for soldier-worn or vehicle-mounted deployment. BLDS represents a “leap ahead” in survivability and tactical awareness. Prototypes are now being finalized and will undergo operational testing this year, with fully networked versions expected by fall 2025 .

Aptevo Therapeutics (NASDAQ:APVO) reported 85% remission rates in unfit AML patients from its ongoing Phase 1b/2 RAINIER trial, which evaluates mipletamig, a CD123 x CD3 bispecific antibody. The mipletamig + venetoclax/azacitidine combination outperformed historical benchmarks and demonstrated no CRS or dose-limiting toxicities . Remarkably, one patient advanced to stem cell transplant —a rare outcome in this high-risk group. CEO Marvin White emphasized mipletamig’s differentiated CD3 engineering strategy , positioning it as a potential new frontline standard in AML treatment.

Sharps Technology (NASDAQ:STSS) is scaling operations with the second shipment under its $50 million SoloGard syringe agreement , alongside major manufacturing upgrades. Enhancements include advanced injection molding, 10x energy-efficient equipment, and optimized cleanroom infrastructure. Sharps is executing a $400,000 order as part of a five-year deal to supply up to 500 million FDA- and WHO-approved SoloGard smart syringes .

Arqit Quantum (NASDAQ:ARQQ) was named an inaugural member of the Oracle Defense Ecosystem (NYSE:ORCL) during the Oracle Defense Tech Summit in Austin, TX. The initiative focuses on reshaping defense innovation and infrastructure modernization. Arqit’s quantum-safe encryption solutions are gaining attention for their ability to secure mission-critical systems against future cyber threats. Its Senior Director spotlighted the company’s role in protecting data in a post-quantum world , reinforcing Arqit’s strategic value in national security tech stacks.

Please go to https://247marketnews.com/venu-disclosure/ for additional 247marketnews.com VENU disclosure.

The post Hot Stocks in the News – June 18, 2025 appeared first on 24/7 MarketNews .

For further details see: